Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Hangzhou Tigermed Consulting Co's Debt-to-EBITDA or its related term are showing as below:
FRA:5HZ1'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.16 Med: 0.94 Max: 2.51
Current: 1.56
During the past 13 years, the highest Debt-to-EBITDA Ratio of Hangzhou Tigermed Consulting Co was 2.51. The lowest was 0.16. And the median was 0.94.
FRA:5HZ1's Debt-to-EBITDA is ranked better than 60.71% of 112
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.26
vs FRA:5HZ1: 1.56
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Hangzhou Tigermed Consulting Co Debt-to-EBITDA Related Terms
Hangzhou Tigermed Consulting Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Tigermed Consulting Co Debt-to-EBITDA Chart
FRA:5HZ1 vs TMO, DHR, IDXX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Hangzhou Tigermed Consulting Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Tigermed Consulting Co Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Hangzhou Tigermed Consulting Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Hangzhou Tigermed Consulting Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Hangzhou Tigermed Consulting Co (FRA:5HZ1) has a Debt-to-EBITDA of 2.15 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Hangzhou Tigermed Consulting Co. This is 129% above median its historical median of 0.94. Over the past decade, Hangzhou Tigermed Consulting Co's Debt-to-EBITDA has ranged from 0.16 to 2.51. According to the industry distribution chart, Hangzhou Tigermed Consulting Co ranks #44 out of 112 companies in the Medical Diagnostics & Research industry, placing it in the top 39.3%.
Is Hangzhou Tigermed Consulting Co's Debt-to-EBITDA too high?
Hangzhou Tigermed Consulting Co's current Debt-to-EBITDA of 2.15 is 129% above median its 10-year median of 0.94. Over the past 10 years, this metric has ranged from a low of 0.16 to a high of 2.51. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.26. Hangzhou Tigermed Consulting Co's value of 2.15 is 4.9% below this industry median. Based on the distribution chart, Hangzhou Tigermed Consulting Co ranks #44 out of 112 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Hangzhou Tigermed Consulting Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Tigermed Consulting Co's Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Hangzhou Tigermed Consulting Co ranks #44 out of 112 companies for Debt-to-EBITDA. This puts Hangzhou Tigermed Consulting Co in the upper half of its industry. The industry median Debt-to-EBITDA is 2.26. Hangzhou Tigermed Consulting Co's value of 2.15 is 4.9% below this benchmark. Historically, Hangzhou Tigermed Consulting Co's own Debt-to-EBITDA has ranged from 0.16 to 2.51 over the past decade. While the company's 10-year median is 0.94 vs. the industry median of 2.26, Hangzhou Tigermed Consulting Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.26, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hangzhou Tigermed Consulting Co's current Debt-to-EBITDA of 2.15 is 4.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Hangzhou Tigermed Consulting Co. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou Tigermed Consulting Co's current Debt-to-EBITDA is 2.15, which is 129% above median its own 10-year median of 0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Tigermed Consulting Co stock overvalued right now?
Hangzhou Tigermed Consulting Co (FRA:5HZ1) has a current Debt-to-EBITDA of 2.15. The stock's GF Value™ is €5.42, compared to a current price of €4.32 — trading 20.3% below its estimated fair value. The current Debt-to-EBITDA is 2.15, which is 129% above median its 10-year median of 0.94 and 4.9% below the Medical Diagnostics & Research industry median of 2.26. Hangzhou Tigermed Consulting Co's overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Hangzhou Tigermed Consulting Co (FRA:5HZ1), the current Debt-to-EBITDA is 2.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou Tigermed Consulting Co (FRA:5HZ1) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co stock appears to be undervalued.
The current stock price of €4.32 is trading 20.3% below its estimated GF Value™ of €5.42.
Key valuation signals for FRA:5HZ1:
Debt-to-EBITDA: 2.15 (129% above median its 10-year median of 0.94)
GF Value™: €5.42 vs. price of €4.32 (20.3% below fair value)
Industry Position: 4.9% below the Medical Diagnostics & Research median (#44 of 112)
No single metric tells the full story. See the FRA:5HZ1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hangzhou Tigermed Consulting Co Ltd is a China-based provider of comprehensive biopharmaceutical R&D services, with an expanding world-wide presence. The Group is principally engaged in CRO services.
89GF Score
Get the complete analysis for FRA:5HZ1
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5HZ1 has been successfully added to your 
